Department of Laboratory Medicine, The Renmin Hospital of Wuhan University, Wuhan, 410060 Hubei Province, China.
Department of Laboratory Medicine, The Maternal and Child Hospital of Hubei Province, Tongji Medical College, The Huazhong University of Science and Technology, Wuhan, 410060 Hubei Province, China.
Dis Markers. 2020 Sep 18;2020:8871746. doi: 10.1155/2020/8871746. eCollection 2020.
Accumulating evidence implies that long noncoding RNAs (lncRNAs) play a crucial role in predicting survival for glioma patients. However, the potential function of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) in tumors remained largely unclear. The aim of this study was to explore the expression of lncRNA ELF3-antisense RNA 1 (ELF3-AS1) and evaluate its functions in glioma patients. . ELF3-AS1 expressions were examined by RT-PCR in 182 pairs of glioma specimens and adjacent normal tissues. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ELF3-AS1. The chi-square tests were used to examine the associations between ELF3-AS1 expression and the clinicopathological characters. The overall survival (OS) and disease-free survival (DFS) were analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. The prognostic value of the ELF3-AS1 expression in glioma patients was further analyzed using univariate and multivariate Cox regression analyses. Loss-of-function assays were performed to determine the potential function of ELF3-AS1 on the proliferation and invasion of glioma cells.
The ELF3-AS1 expression level was significantly higher in glioma specimens compared with adjacent nontumor specimens ( < 0.01). A high expression of ELF3-AS1 was shown to be associated with the WHO grade ( = 0.023) and KPS score ( = 0.012). ROC assays revealed that high ELF3-AS1 expression had an AUC value of 0.8073 (95% CI: 0.7610 to 0.8535) for glioma. Using the Kaplan-Meier analysis, we found that patients with a high ELF3-AS1 expression had significantly poor OS ( = 0.006) and DFS ( = 0.0002). In a multivariate Cox model, we confirmed that ELF3-AS1 expression was an independent poor prognostic factor for glioma patients. The functional assay revealed that knockdown of ELF3-AS1 suppressed the proliferation and invasion of glioma cells.
Our findings confirmed that ELF3-AS1 functions as an oncogene in glioma and indicated that ELF3-AS1 is not only an important prognostic marker but also a potential therapy target for glioma.
越来越多的证据表明，长非编码 RNA（lncRNA）在预测胶质瘤患者的生存中起着至关重要的作用。然而，lncRNA ELF3-反义 RNA 1（ELF3-AS1）在肿瘤中的潜在功能仍很大程度上不清楚。本研究旨在探讨 lncRNA ELF3-反义 RNA 1（ELF3-AS1）的表达，并评估其在胶质瘤患者中的功能。
通过 RT-PCR 检测 182 对胶质瘤标本和相邻正常组织中的 lncRNA ELF3-AS1 表达。绘制接收者操作特征（ROC）曲线以估计 ELF3-AS1 的诊断价值。使用卡方检验检验 ELF3-AS1 表达与临床病理特征之间的关联。通过对数秩检验分析总生存（OS）和无病生存（DFS），并根据 Kaplan-Meier 绘制生存曲线。使用单变量和多变量 Cox 回归分析进一步分析 ELF3-AS1 表达在胶质瘤患者中的预后价值。进行功能丧失实验以确定 ELF3-AS1 对胶质瘤细胞增殖和侵袭的潜在功能。
ELF3-AS1 表达水平在胶质瘤标本中明显高于相邻非肿瘤标本（<0.01）。高 ELF3-AS1 表达与 WHO 分级（=0.023）和 KPS 评分（=0.012）相关。ROC 检测显示，高 ELF3-AS1 表达对胶质瘤的 AUC 值为 0.8073（95%CI：0.7610 至 0.8535）。通过 Kaplan-Meier 分析，我们发现高 ELF3-AS1 表达的患者 OS（=0.006）和 DFS（=0.0002）明显较差。在多变量 Cox 模型中，我们证实 ELF3-AS1 表达是胶质瘤患者独立的不良预后因素。功能测定显示，敲低 ELF3-AS1 抑制了胶质瘤细胞的增殖和侵袭。
我们的研究结果证实 ELF3-AS1 在胶质瘤中起癌基因作用，并表明 ELF3-AS1 不仅是重要的预后标志物，也是胶质瘤的潜在治疗靶点。
